Adit L. Tal
Experienced in Infantile Neutropenia

Dr. Adit L. Tal

Hematology | Oncology
Montefiore Einstein
The Children's Hospital At Montefiore
3415 Bainbridge Avenue, 
Bronx, NY 
Clinical Trials:Currently Recruiting for 6 Trials

Experienced in Infantile Neutropenia
Montefiore Einstein
The Children's Hospital At Montefiore
3415 Bainbridge Avenue, 
Bronx, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adit Tal, MD, is an Attending Physician at Children’s Hospital at Montefiore Einstein (CHAM) and an Assistant Professor of Pediatric Hematology, Oncology, Marrow and Blood Cell Transplantation at our Albert Einstein College of Medicine. Since joining the Montefiore team, Dr. Tal’s clinical focus has been the treatment of pediatric leukemia and lymphoma, and the supportive care of children with cancer.

Dr. Tal is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Gliomatosis Cerebri, Infantile Neutropenia, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 13 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Infantile Neutropenia.

Graduate Institution
Sackler School Of Medicine, Tel Aviv University
Residency
Montefiore Medical Center
Specialties
Hematology
Oncology
Fellowships
Children's Hospital at Montefiore
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Archcare
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Hamaspik
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
The Wellness Plan Medical Centers
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

The Children's Hospital at Montefiore
3415 Bainbridge Avenue, Bronx, NY 10467
Call: 718-741-2342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


17 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Procedure, Other, Drug
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Gemtuzumab, Gilteritinib, Liposomal Daunorubicin, Liposomal Cytarabine, Methotrexate, Mitoxantrone, Hydrocortisone
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Enrollment Status: Recruiting
Publish Date: September 10, 2025
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
View 11 Less Clinical Trials

13 Total Publications

Pediatric Hematology Oncology Building Education and Training Success (PHO BEATS): A Conference to Raise Awareness and Interest for Residents and Medical Students.
Pediatric Hematology Oncology Building Education and Training Success (PHO BEATS): A Conference to Raise Awareness and Interest for Residents and Medical Students.
Journal: Pediatric blood & cancer
Published: March 03, 2025
View All 13 Publications
Similar Doctors
Advanced in Infantile Neutropenia
Dr. Cara A. Rosenbaum
Hematology Oncology | Oncology | Hematology
Advanced in Infantile Neutropenia
Dr. Cara A. Rosenbaum
Hematology Oncology | Oncology | Hematology

Weill Medical College Of Cornell

428 E 72nd St, Ofc 300, 
New York, NY 
 (8.7 miles away)
212-746-7566
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Cara Rosenbaum is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Rosenbaum is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration.

Lisa M. Gennarini
Experienced in Infantile Neutropenia
Dr. Lisa M. Gennarini
Hematology | Oncology
Experienced in Infantile Neutropenia
Dr. Lisa M. Gennarini
Hematology | Oncology

The Children's Hospital At Montefiore

3415 Bainbridge Avenue, 
Bronx, NY 
 (0.1 miles away)
718-741-2342
Languages Spoken:
English
See accepted insurances

Lisa Gennarini, MD, has been an Assistant Professor of Pediatrics in the Division of Pediatric Hematology/Oncology and Blood & Marrow Cell Transplantation at Children's Hospital at Montefiore (CHAM) since 2014. Her clinical focus is on treatment of children with leukemia and lymphoma as well as various vascular anomalies. She is also the CHAM Principal Investigator for Children?s Oncology Group trials, and also leads the CHAM Vascular Malformations Program. Dr. Gennarini graduated from Siena College in 2004, earning her Bachelor of Science in Biology. In 2008, she received her Doctor of Medicine at State University of New York, Upstate Medical University in Syracuse. She began a residency in Pediatrics at Jefferson Medical College/A.I. duPont Hospital for Children, followed by a fellowship in Pediatric Hematology/Oncology at Children?s Hospital at Montefiore. Dr. Gennarini's work on pediatrics, topics ranging from sickle cell disease to implementing communications skills training courses in pediatric hematology/oncology, has been published in various journals and books, and presented nationally. Dr. Gennarini is board certified by the American Board of Pediatrics in Pediatric Hematology/Oncology and General Pediatrics. Dr. Gennarini is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Neuroblastoma, Bone Marrow Aspiration, and Adenoidectomy.

Experienced in Infantile Neutropenia
Dr. Andrew M. Evens
Hematology | Hematology Oncology | Oncology
Experienced in Infantile Neutropenia
Dr. Andrew M. Evens
Hematology | Hematology Oncology | Oncology

Rutgers Health-Rwj Scleroderma Program

1 Robert Wood Johnson Pl, 
New Brunswick, NJ 
 (40.0 miles away)
732-828-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Evens is a Hematologist and a Hematologist Oncology provider in New Brunswick, New Jersey. Dr. Evens is rated as an Elite provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Evens is currently accepting new patients.

VIEW MORE INFANTILE NEUTROPENIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tal's expertise for a condition
ConditionClose
        • Experienced
        • Bone Marrow Aspiration
          Dr. Tal is
          Experienced
          . Learn about Bone Marrow Aspiration.
          See more Bone Marrow Aspiration experts
        • Gliomatosis Cerebri
          Dr. Tal is
          Experienced
          . Learn about Gliomatosis Cerebri.
          See more Gliomatosis Cerebri experts
        • Infantile Neutropenia
          Dr. Tal is
          Experienced
          . Learn about Infantile Neutropenia.
          See more Infantile Neutropenia experts
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile
        For Patients
        • Our Story
        • How MediFind Works
        • Conditions A-Z
        • Doctor Directory
        • Symptoms Directory
        • Procedures Directory
        • Treatment Directory
        • Drug Directory
        • Infusion Center Finder
        • FAQ
        • Contact Us
        For Providers and Practices
        • Claim Your Profile
        • Newsroom
        Business Solutions
        • Provider
        • Network Solutions
        Additional Resources
        • Consumer Health Data Privacy Policy
        • Privacy Policy
        • Terms of Use
        • Advertising Policy
        • Content Policy
        Subscribe to our newsletter

        Sign up to stay informed about MediFind and get wellness sent your way.

        Close

          By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

          Bullet PinMediFind
          Follow us on
          This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
          © 2026 All Rights Reserved

          Request an Appointment

          If you are experiencing a medical emergency, call 9-1-1.

          MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

          Patient Details

          This information is for the patient who will be seen at the appointment.

            Close

            Returning patient? Use your address on file with the provider.

            Insurance Details

            Please provide information of the primary insurance holder as the practice may require this information to schedule.

            Insurance Provider *
            Insurance ProviderClose

            Appointments Details

            Let’s get more information about your appointment.

                    0 / 1000
                    0 / 1000
                    By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.